Roche goes beyond licensing in deal with Chinese biotech

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get straight to the news. The need-to-know this morning Bristol Myers Squibb said Zenbexus, recently granted FDA accelerated approval to treat multiple myeloma, reduced the risk of disease progression by 51% compared to standard therapy in a Phase 3 trial. Generic drugmaker Viatris said it will acquire Pacira Biosciences , maker of non-opioid pain therapies, for $1.65 billion. Roche goes beyond licensing in deal with Chinese biotech Over the past few years, pharma companies…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Let’s get straight to the news.

The need-to-know this morning

Bristol Myers Squibb said Zenbexus, recently granted FDA accelerated approval to treat multiple myeloma, reduced the risk of disease progression by 51% compared to standard therapy in a Phase 3 trial.
Generic drugmaker Viatris said it will acquire Pacira Biosciences, maker of non-opioid pain therapies, for $1.65 billion.

Roche goes beyond licensing in deal with Chinese biotech

Over the past few years, pharma companies have flocked to China to license existing drug candidates. Roche is taking a new approach, partnering with Chinese startup Defand Therapeutics to discover new medicines.

Continue to STAT+ to read the full story…